RankAlpha logo
Back to Rankings

VVOS

Vivos TherapeuticsD
Nasdaq / Health Care Equipment & Services
Last Price
$0.10+$0.00 (+2.40%)
At close · 2026-11-13
View Chart
Current thesis
Nevada sleep-service growth and the conditional restoration of Nasdaq equity compliance improve the operating and listing outlook. The SOD interest offers optionality, but no commercialization revenue is established.
Posture
Defensive
Lead driver
Momentum
What changed
Next scheduled catalyst: earnings 2026-11-17.
What can break
June 30 cash was $1.8 million against a Q2 net loss of $5.5 million, leaving substantial financing risk. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
Momentum
93
Value
36
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.08 · Bull $0.16 · Bear $0.03Analysis 2026-11-11; returns require an exact persisted reference.
Earnings
2026-11-17
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-13 • Vendor: Data Vendor v1
Scores
As of 2026-11-16 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-11-16

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-16. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $0.75
Why
Momentum93 · Δ7d -
Value36 · Δ7d -0.1
Sentiment41 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-11-17.
  • • Momentum remains the lead driver in the composite.

Contradictions & invalidation

  • • June 30 cash was $1.8 million against a Q2 net loss of $5.5 million, leaving substantial financing risk. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
  • • Nasdaq’s equity-compliance determination may be revisited after the next periodic report. [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm
  • • Liquidity, operating losses, potential common-share issuance and the need to demonstrate continuing Nasdaq compliance could overwhelm revenue growth.

Catalyst clock

2026-11-17

Next filing must substantiate Nasdaq equity compliance

Lead driver: Momentum · See technicals
Momentum
93
18% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
43% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
41
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade D. Momentum 93.1 / Value 36.3 / Sentiment 40.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-11. Scenario method

B+
Bull case
20%
Probability
Target price
$0.16
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.03
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-11-13
Market Cap
$3.29M
Beta
6.89
Shares Out
33.61M
P/E (TTM) · Derived
-0.0
P/S (TTM)
1.28
P/FCF (TTM) · Derived
-0.06
Rev YoY
+34.9%
EPS YoY
-43.8%
Gross Margin
+53.3%
Op Margin
-107.9%
Net Debt
$11.47M
Current Ratio
0.21
As of 2026-11-16 • Updated nightlySource: Internal modelMethods & Data